会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Novel Regulators of the Innate Immune System
    • 先天免疫系统的新型调节器
    • US20110236455A1
    • 2011-09-29
    • US13121029
    • 2009-09-28
    • Peter ZipfelChristina SkerkaReinhard Wallich
    • Peter ZipfelChristina SkerkaReinhard Wallich
    • A61K38/17C07K14/46A61M31/00C07K16/18C12N5/16G01N33/577A61P29/00A61L33/12
    • A61L27/54A61K38/00A61L27/22A61L2300/252A61L2300/256A61L2300/41A61L2300/434C07K14/472C07K14/811C07K16/18G01N33/92G01N2800/347
    • The present invention relates to the identification of novel regulators of the innate immune system, in particular the complement system. More particularly, the present invention relates to specific C5 convertase inhibitors. These novel inhibitors are particularly useful for treating inflammatory diseases involving the complement system. In a first aspect, the present invention focuses on the use of CFHR proteins and functional fragments or functional derivatives thereof for preventing inflammatory reactions. In a further aspect, the present invention focuses on the use of said CFHR proteins for inactivating complement activation during transplantation and dialysis and for coating devices which come into contact with blood or body fluids, in particular implants. The invention furthermore provides a pharmaceutical composition comprising functional CFHR protein in combination with functional factor H. In a further aspect, the present invention focuses on providing monoclonal antibodies which specifically detect CFHR proteins, and on the use thereof in methods of determining CFHR in body fluids. These methods are particularly suitable for diagnosing inflammatory diseases.
    • 本发明涉及先天免疫系统,特别是补体系统的新型调节剂的鉴定。 更具体地说,本发明涉及具体的C5转化酶抑制剂。 这些新型抑制剂特别适用于治疗涉及补体系统的炎性疾病。 在第一方面,本发明着重于CFHR蛋白及其功能片段或其功能衍生物用于预防炎症反应的用途。 在另一方面,本发明着重于所述CFHR蛋白在移植和透析期间灭活补体活化以及与血液或体液(特别是植入物)接触的涂覆装置的用途。 本发明还提供了包含与功能性因子H组合的功能性CFHR蛋白质的药物组合物。在另一方面,本发明着重于提供特异性检测CFHR蛋白质的单克隆抗体,以及在确定体液中CFHR的方法中的用途 。 这些方法特别适用于诊断炎性疾病。
    • 5. 发明申请
    • REGULATORY PROTEIN PKE#83 FROM HUMAN KERATINOCYTES
    • 人类KERATINOCYTES的调节蛋白PKE#83
    • US20070154911A1
    • 2007-07-05
    • US11566115
    • 2006-12-01
    • Michael KramerMichael BechtelJeanette ReinartzBirgit SchaeferReinhard Wallich
    • Michael KramerMichael BechtelJeanette ReinartzBirgit SchaeferReinhard Wallich
    • C12Q1/68C07H21/04C12P21/06C07K14/78
    • C07K16/18C07K14/4702
    • The invention relates to an isolated polypeptide which is the same as or similar to (i.e., has the same function and effect as) a protein which occurs naturally in human keratinocytes and is more strongly expressed when the keratinocytes are in their activated state. The invention also relates to an isolated nucleic acid which codes a polypeptide or protein of this type that is typical for human keratinocytes and to the use of said polypeptide and said nucleic acid for detection, especially diagnostic purposes and/or for therapeutic purposes or the use of reagents, especially recombinant vector molecules and antibodies, against molecules of this type. The inventive protein has the amino acid sequence shown in sequence protocol SEQ ID NO:3 or an allele or derivative of this amino acid sequence produced therefrom by amino acid substitution, deletion, insertion, or inversion, and the inventive nucleic acid has either the amino acid sequence shown in sequence protocol SEQ ID NO:1 or a nucleotide sequence complementary thereto or a partial sequence of one of these two nucleotide sequences or a nucleotide sequence which is completely or partially hybridizable one of these two nucleotide sequences.
    • 本发明涉及与角质形成细胞处于其活化状态时天然存在的蛋白质相同或相似(即具有与之相同的功能和作用)的分离多肽。 本发明还涉及编码这种类型的多肽或蛋白质的分离的核酸,其是人角质形成细胞的典型特征,以及使用所述多肽和所述核酸进行检测,特别是诊断目的和/或用于治疗目的或使用 的试剂,特别是重组载体分子和抗体。 本发明的蛋白质具有序列方案SEQ ID NO:3所示的氨基酸序列或通过氨基酸取代,缺失,插入或倒位从其产生的该氨基酸序列的等位基因或衍生物,并且本发明的核酸具有氨基酸 序列方案SEQ ID NO:1所示的酸序列或其互补的核苷酸序列或这两个核苷酸序列之一的部分序列或这两个核苷酸序列之一完全或部分杂交的核苷酸序列。